Gupta et al. reported that PARK2 deficiency hyperactivates PI3K/AKT pathway and this outcome was dependent on PTEN, suggesting that PARK2 loss directly or indirectly impaired the anti-tumor function of PTEN (110). This evidence concerns the gene PRKN and neoplasm.